Processing

Please wait...

Settings

Settings

Goto Application

1. WO1998014217 - METHODS AND MEANS FOR THE TREATMENT OF MALIGNANCIES

Publication Number WO/1998/014217
Publication Date 09.04.1998
International Application No. PCT/NL1997/000542
International Filing Date 30.09.1997
Chapter 2 Demand Filed 29.04.1998
IPC
A61K 38/19 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
A61K 38/20 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 48/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
CPC
A61K 38/2006
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins [IL]
2006IL-1
A61K 38/202
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins [IL]
202IL-3
A61K 39/0011
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
0005Vertebrate antigens
0011Cancer antigens
A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applicants
  • INTROGENE B.V. [NL]/[NL] (AllExceptUS)
  • BOUT, Abraham [NL]/[NL] (UsOnly)
  • VAN BEKKUM, Dirk, Willem [NL]/[NL] (UsOnly)
Inventors
  • BOUT, Abraham
  • VAN BEKKUM, Dirk, Willem
Agents
  • SMULDERS, Th., A., H., J.
Priority Data
96202725.630.09.1996EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND MEANS FOR THE TREATMENT OF MALIGNANCIES
(FR) METHODES ET MOYENS PERMETTANT DE TRAITER DES PATHOLOGIES MALIGNES
Abstract
(EN)
The present invention provides novel means and methods for eliminating unwanted cells or organisms from a (mammalian) subject. In particular tumors can be combatted using the compositions according to the present invention. In a preferred embodiment solid tumors are injected with a burst of cytokine (in particular IL-1a or IL-3) together with a slow release source for a cytokine. To further boost the immune system an adjuvans is preferred. In a preferred embodiment the source for the slow release cytokine is a recombinant adenovirus. In an especially preferred embodiment the adjuvant comprises inactivated (cracked) adenovirus producing cells.
(FR)
Nouveaux moyens et méthodes permettant d'éliminer des cellules ou organismes indésirables chez un sujet (mammifère). L'utilisation des compositions selon la présente invention permet en particulier de lutter contre les tumeurs. Dans un mode de réalisation préféré, on injecte dans des tumeurs solides une certaine quantité de cytokine (en particulier IL-1a ou IL-3) ainsi qu'une source de libération lente de cytokine. Pour stimuler encore plus le système immunitaire, on emploie également un adjuvant. Dans un mode de réalisation préféré, la source pour la libération lente de cytokine est un adénovirus de recombinaison. Dans un mode de réalisation particulièrement préféré, l'adjuvant comporte des cellules de production d'adénovirus inactivées (décomposées).
Also published as
Latest bibliographic data on file with the International Bureau